Prostate Cancer Diagnostics Market
Prostate Cancer Diagnostics Market Study by PSA, PCA3, and CTC Tests for Hospitals, Independent Diagnostic Laboratories, and Cancer Research Institutes from 2024 to 2034
Analysis of Prostate Cancer Diagnostics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Prostate Cancer Diagnostics Market Outlook (2024 to 2034)
The global prostate cancer diagnostics market is estimated at a value of US$ 4.18 billion in 2024. As per this recently published report by Fact.MR, worldwide revenue from prostate cancer diagnostics is projected to rise at a CAGR of 10% and reach US$ 10.84 billion by 2034.
Prostate cancer is one of the most common types of cancer in men. The rising cases of prostate cancer are driving high demand for effective diagnostic solutions. The risk of prostate cancer increases with age. High obesity leads to prime chances of having prostate cancer. Several studies suggest that prostate cancer growth is more aggressive in obese people.
Awareness regarding regular check-ups and early treatments is expected to drive the demand for advanced prostate cancer diagnostic technologies. Additionally, the absence of a one-test-fits-all approach to prostate cancer is pushing people to focus on timely detection.
Increasing geriatric population across the world along with continuous innovations in the healthcare sector is expected to uplift the prostate cancer diagnostics market growth in the coming years. The rising healthcare spending by governments worldwide is further generating opportunities for prostate cancer diagnostic solution providers.
- The North American prostate cancer diagnostics market size is projected to reach US$ 2.63 billion by 2034.
- East Asia is expected to capture 22.4% of the global prostate cancer diagnostics market share in 2024.
| Report Attribute | Detail |
|---|---|
| Prostate Cancer Diagnostics Market Size (2024E) | US$ 4.18 Billion |
| Forecasted Market Value (2034F) | US$ 10.84 Billion |
| Global Market Growth Rate (2024 to 2034) | 10% CAGR |
| South Korea Market Value (2034F) | US$ 578.5 Million |
| CTC Test Demand Growth Rate (2024 to 2034) | 12.9% CAGR |
| Key Companies Profiled | Bayer AG; F. Hoffmann-La Roche Ltd; ACON Laboratories, Inc.; HUMASIS; Vyant Bio Inc.; Danaher Corporation; Teco Diagnostics; Hologic Inc.; Abbott Laboratories; Biocept Inc.; AstraZeneca Plc.; AccuQuik Test Kits; MDxHealthcare; Siemens Healthcare GmbH; OPKO Health Inc.; Foundation Medicine Inc.; Myriad Genetics Inc.; DiaSorin S.p.A; bioMérieux SA; Metamark Genetics, Inc.; Prostatype Genomics; Fujirebio; Becton Dickinson and Company; Agilent Technologies; Proteomedix; Eurolyser Diagnostica GmbH. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is a Key Prostate Cancer Diagnostics Market Trend?
“Integration of Digital Technologies to Offer Accurate and Reliable Prostate Cancer Diagnostic Solutions”
Development of improved screening techniques is one of the notable prostate cancer diagnostics market trends. Effective prostate cancer treatment depends upon early detection. Advanced cancer diagnostic technologies can help to get quick and accurate screening of disease. Prostate-specific antigen (PSA) testing is one of the effective technologies in the early detection of prostate cancer. Liquid biopsy and DNA probes-based diagnostic solutions are also effective in cancer detection.
Integration of artificial intelligence (AI) and machine learning (ML) algorithms is set to offer reliable and accurate diagnostic solutions. Digital technologies such as AI, ML, the Internet of Things (IoT), and predictive data analytics are contributing to the development of advanced imaging technologies such as positron emission tomography (PET), magnetic resonance imaging (MRI), and multiparametric MRI. These technologies are effective in providing accurate images of the prostate gland aiding doctors to identify abnormalities and implement efficacious treatment procedures. Thus, technological advancements are projected to boost the profits of prostate cancer diagnostic technology providers.
Which Issues Should Prostate Cancer Diagnostic Solution Producers Focus On?
“Lack of Awareness and High Costs Associated with Diagnosis”
Even though technological breakthroughs are expected to offer high-growth opportunities for prostate cancer diagnostic solution providers lack of knowledge or awareness of cancer type is expected to hamper their revenue growth to some extent. People in developing countries are unaware of the prostate cancer and its symptoms. Leading manufacturers should focus on awareness programs to increase the early detection of disease.
High costs of screening are also one of the factors hampering the prostate cancer diagnostic solution sales growth. Patients with low income are often deterred from being diagnosed with cancer due to high screening costs.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Start-Up Ecosystem
- Enrich Bioscience is a Canada-based start-up that offers DNA methylation detection solutions for cancer diagnosis. By detecting anomalous DNA methylation, the start-up's solution offers accurate and specific methylation data. This solution is effective in performing accurate, non-invasive cancer screening for individuals.
- SAGA Diagnostics is a Swedish start-up that offers dPCR testing technology for cancer detection. The company’s SAGAsafe solutions provide accurate detection of various cancer types through a non-invasive in-vitro diagnostic (IVD) kit.
Country-wise Analysis
Why is the United States Ahead in Cancer Care Innovation?
“Sophisticated Healthcare Institutions Offering Advanced Prostate Cancer Diagnostic Technologies”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 444.6 Million |
| Growth Rate (2024 to 2034) | 10.5% CAGR |
| Projected Value (2034F) | US$ 1.2 Billion |
- As per estimations by to American Cancer Society in 2024 about 299,010 new cases of prostate cancer are expected to be detected in the United States.
Prevalence of prostate cancer and the presence of advanced healthcare infrastructure are expected to push the sales of prostate cancer diagnostic technologies in the United States in the years ahead. Strong existence of biotech firms and research institutions in the United States is further leading to the development of advanced prostate cancer screening technologies.
Why are Prostate Cancer Diagnostic Solution Producers Expected to Do Well in Japan?
“High Presence of Target Patients Driving Need for Advanced and Reliable Prostate Cancer Diagnostic Technologies”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 270.6 Million |
| Growth Rate (2024 to 2034) | 10.5% CAGR |
| Projected Value (2034F) | US$ 736.3 Million |
Strong presence of an aging population who are more prone to chronic disorders such as cancer is anticipated to offer profitable opportunities for prostate cancer diagnostic service providers. Aged men have a high chance of having prostate cancer. Japan is also ahead in technological innovations and the medical sector is no exception. Thus, the high patient pool and availability of advanced diagnosis technologies are driving the market growth in Japan.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Why are Sales of Prostate-Specific Antigen (PSA) Tests High?
“PSA Tests Effective in Early Cancer Tumor Detection”
| Attribute | PSA Tests |
|---|---|
| Segment Value (2024E) | US$ 1.66 Billion |
| Growth Rate (2024 to 2034) | 9.8% CAGR |
| Projected Value (2034F) | US$ 4.21 Billion |
Prostate-specific antigen (PSA) tests are projected to exhibit high sales during the study period (2024 to 2034). Prostate-specific antigen tests can detect small and unrecognized cancer cells effectively. This test can detect cancer tumors before the occurrence of symptoms. Thus, the demand for PSA tests is high.
Which End User Accounts for High Revenue Generation?
“Hospitals Prime Preference for Treatment of Prostate Cancer”
| Attribute | Hospitals |
|---|---|
| Segment Value (2024E) | US$ 1.41 Billion |
| Growth Rate (2024 to 2034) | 9.7% CAGR |
| Projected Value (2034F) | US$ 3.57 Billion |
Patients primarily prefer hospitals for the diagnosis and treatment of chronic disorders. The presence of advanced healthcare technologies and skilled professionals makes hospitals the prime preference for treatment procedures. Hospitals are also well known for effective chronic disease treatment such as cancer. Hospitals offer various range of services including initial screening to advanced treatment.
Competitive Landscape
Key players in the prostate cancer diagnostics market are focused on integrating the digital technologies such as artificial intelligence and machine learning for studying tissue formation and determining the accuracy of the same. The introduction of advanced prostate cancer diagnostic technologies aids leading companies in uplifting their market position and shares.
Collaborations with research institutions and partnerships with other players are expected to boost the product folio and profits of key market players. Regional expansion is also an effective strategy to find opportunities in untapped regions.
- The Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit was launched in April 2022 to improve the early detection of prostate cancer among at-risk populations in New York City.
- In March 2022, miR Scientific and Leonie Hill Capital joined hands for the commercialization of the miR Sentinel™ Prostate Cancer Test in Singapore and Southeast Asia.
Fact.MR provides detailed information about the price points of key providers of prostate cancer diagnostic solutions positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.
Key Segments of Prostate Cancer Diagnostics Market Research
-
By Test Type :
- PSA
- PCA3
- CTC
- Others
-
By End User :
- Hospitals
- Independent Diagnostic Laboratories
- Cancer Research Institutes
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Test Type 6.2. End User 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Test Type 7.1. PSA 7.2. PCA3 7.3. CTC 7.4. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User 8.1. Hospitals 8.2. Independent Diagnostic Laboratories 8.3. Cancer Research Institutes 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. East Asia 9.6. South Asia & Pacific 9.7. Middle East & Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Test Type, End User, and Region for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Bayer AG 19.2. F. Hoffmann-La Roche Ltd 19.3. ACON Laboratories, Inc. 19.4. HUMASIS 19.5. Vyant Bio Inc. 19.6. Danaher Corporation 19.7. Teco Diagnostics 19.8. Hologic Inc. 19.9. Abbott Laboratories 19.10. Biocept Inc. 19.11. AstraZeneca Plc. 19.12. AccuQuik Test Kits 19.13. MDxHealthcare 19.14. Siemens Healthcare GmbH 19.15. OPKO Health Inc. 19.16. Foundation Medicine Inc. 19.17. Myriad Genetics Inc. 19.18. DiaSorin S.p.A 19.19. bioMérieux SA 19.20. Metamark Genetics, Inc. 19.21. Prostatype Genomics 19.22. Fujirebio 19.23. Becton Dickinson and Company 19.24. Agilent Technologies 19.25. Proteomedix 19.26. Eurolyser Diagnostica GmbH 20. Assumptions and Acronyms Used 21. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 10: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 11: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 12: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 19: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 20: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 21: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 22: Latin America Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 23: Latin America Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 24: Latin America Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 28: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 29: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 30: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 31: Western Europe Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 32: Western Europe Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 33: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 34: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 35: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 36: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 37: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Eastern Europe Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 41: Eastern Europe Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 42: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 43: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 44: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 45: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 46: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: East Asia Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 50: East Asia Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 51: East Asia Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 52: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 53: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 54: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 55: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 56: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 57: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 58: South Asia & Pacific Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 59: South Asia & Pacific Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 60: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 61: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 62: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 63: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 64: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 65: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 66: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 67: MEA Market Value (US$ Mn) Analysis, by Test Type, 2019 to 2023
Table 68: MEA Market Value (US$ Mn) Analysis, by Test Type, 2024 to 2034
Table 69: MEA Market Value (US$ Mn) Opportunity Analysis, by Test Type, 2024 to 2034
Table 70: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 71: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 72: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by End User, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 14: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 15: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 16: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 17: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 18: North America Market Share Analysis by Country, 2024 & 2034
Figure 19: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 20: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 21: North America Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 27: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 28: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 29: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 30: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 31: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 32: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 33: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 34: Latin America Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 35: Latin America Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 36: Latin America Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 37: Latin America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 40: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 41: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 42: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 43: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 44: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 45: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 46: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 47: Western Europe Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 48: Western Europe Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 49: Western Europe Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 50: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 51: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 52: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 53: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 54: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 55: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 56: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 57: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 58: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 59: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 60: Eastern Europe Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 61: Eastern Europe Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 62: Eastern Europe Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 63: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 64: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 65: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 66: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 70: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 71: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: East Asia Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 74: East Asia Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 75: East Asia Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 76: East Asia Market Share and BPS Analysis by End User, 2024 & 2034
Figure 77: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 78: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 79: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 80: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 81: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 82: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 83: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 84: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 85: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 86: South Asia & Pacific Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 87: South Asia & Pacific Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 88: South Asia & Pacific Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 89: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034
Figure 90: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 91: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034
Figure 92: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 93: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 94: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 95: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 96: MEA Market Share Analysis by Country, 2024 & 2034
Figure 97: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 98: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 99: MEA Market Share and BPS Analysis by Test Type, 2024 & 2034
Figure 100: MEA Market Y-o-Y Growth Projections by Test Type, 2024 to 2034
Figure 101: MEA Market Attractiveness Analysis by Test Type, 2024 to 2034
Figure 102: MEA Market Share and BPS Analysis by End User, 2024 & 2034
Figure 103: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 104: MEA Market Attractiveness Analysis by End User, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the prostate cancer diagnostics market in 2024?
The global prostate cancer diagnostics market is approximated at US$ 4.18 billion in 2024.
What is the projected market value for prostate cancer diagnostics by 2034?
The market for prostate cancer diagnostics is forecasted to reach US$ 10.84 billion by 2034.
What is the estimated market growth rate for the next decade?
Demand for prostate cancer diagnostics is foreseen to increase at a CAGR of 10% from 2024 to 2034.
Which region holds a leading market share in 2024?
North America is expected to capture 23.9% of the global market share in 2024.
What is the sales outlook for prostate cancer diagnostics in Japan?
The market in Japan has been calculated to reach US$ 736.3 million by 2034.
Which type of prostate cancer diagnostic test is most widely popular?
PSA test sales are evaluated at US$ 1.66 billion in the year 2024.
Who are the well-known producers of prostate cancer diagnostics solutions?
Leading market players are Bayer AG, F. Hoffmann-La Roche Ltd, ACON Laboratories, Inc., Teco Diagnostics, and Danaher Corporation.
What are the best diagnostics for prostate cancer?
The two most common tests are the digital rectal examination (DRE) and prostate-specific antigen (PSA) blood tests.
Prostate Cancer Diagnostics Market